IQV vs INCY stock comparison
Iqvia vs. Incyte · data as of November 13, 2026
Iqvia (IQV) has a market value of about $43.7B, Incyte (INCY) about $24.7B. Over their latest twelve months Iqvia had revenue of $17.3B and Incyte $6.0B.
On our five checks Incyte scores higher: 2.8 out of 5 (average) against 1.6 (weak).
By area, the stronger company is Iqvia on value; Incyte on future growth; Incyte on financial health; Iqvia on shareholder returns.
Iqvia is cheaper on earnings (P/E 32.3 vs. 61.7), while Incyte grew revenue faster over five years (14.0% vs. 7.5% a year).
Iqvia leads on 12 of the compared lines and Incyte on 7.
Side by side
| IQV | INCY | |
|---|---|---|
| Size and price | ||
| Market cap | $43.7B | $24.7B |
| Share price | $265.12 | $120.97 |
| Score | ||
| Overall score (of 5) | 1.6 | 2.8 |
| Value | 1 | 0 |
| Future growth | 0 | 4 |
| Track record | 3 | 3 |
| Financial health | 1 | 5 |
| Shareholder returns | 3 | 2 |
| Valuation | ||
| P/E (TTM) | 32.3 | 61.7 |
| Forward P/E | 19.2 | 15.1 |
| Price / free cash flow | 21.0 | 36.3 |
| Price / sales | 2.5 | 4.1 |
| EV / EBITDA | 16.8 | 29.5 |
| PEG | 0.80 | — |
| DCF value vs. price | −24% | −48% |
| Business | ||
| Revenue | $17.3B | $6.0B |
| Net income | $1.4B | $403M |
| Free cash flow | $2.1B | $680M |
| Net margin | 8.1% | 6.7% |
| Gross margin (5-yr avg.) | — | 93.5% |
| ROIC (5-yr avg.) | 8.0% | 10.6% |
| Growth | ||
| Revenue growth (1 yr) | 5.9% | 21.2% |
| Revenue growth (5 yrs, per year) | 7.5% | 14.0% |
| EPS growth (5 yrs, per year) | 40.5% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$14.0B | — |
| Dividend yield | None | None |
| Shareholder yield | 2.9% | 0.0% |
| Analysts | ||
| Upside to average target | +18% | +9% |
| Consensus rating | Strong buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: IQV TTM to September 30, 2026, INCY TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Iqvia or Incyte?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Incyte scores 2.8 out of 5 and Iqvia 1.6; the table shows where each one is stronger.
Is Iqvia cheaper than Incyte?
On trailing earnings, Iqvia trades at a P/E of 32.3 and Incyte at 61.7, so Iqvia is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Iqvia or Incyte?
Over five years Incyte grew revenue about 14.0% a year and Iqvia about 7.5% a year.
Full Iqvia analysis → Full Incyte analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.